Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

Tumors often contain areas of oxygen-deficient tissue that frequently withstand conventional therapies. This is because the drugs applied in tumors require oxygen to be effective. An international ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, announced ...

Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly, the oral ...

A subsidiary of GE Healthcare is developing a contrast agent that can help detect nearly invisible colon cancer polyps, according to a report by News Medical. In addition to the mushroom-shaped polyps ...

Australian biotech Telix Pharmaceuticals (NASDAQ:TLX) announced late Tuesday that the U.S. Food and Drug Administration (FDA) has accepted its marketing application for TLX250-CDx and granted it ...